Abstract
Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.
Current Pharmaceutical Biotechnology
Title:Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways
Volume: 18 Issue: 12
Author(s): Elisa Molinelli*, Anna Campanati, Valerio Brisigotti and Annamaria Offidani
Affiliation:
- Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona,Italy
Keywords: Ustekinumab, secukinumab, brodalumab, ixekizumab, efficacy, safety.
Abstract: Background: Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Methods: Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
Results: In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Conclusion: Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
Export Options
About this article
Cite this article as:
Molinelli Elisa*, Campanati Anna, Brisigotti Valerio and Offidani Annamaria, Biologic Therapy in Psoriasis (Part II): Efficacy and Safety of New Treatment Targeting IL23/IL-17 Pathways, Current Pharmaceutical Biotechnology 2017; 18 (12) . https://dx.doi.org/10.2174/1389201019666180103140643
DOI https://dx.doi.org/10.2174/1389201019666180103140643 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
Latest Advancements in Biotherapeutics
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Biologic Agents in the Treatment of Rheumatoid Arthritis
Current Pharmaceutical Biotechnology Fungal Proteins with Antiproliferative and Anticancer Activities
Protein & Peptide Letters Protein Kinases as Tumor Biomarkers and Therapeutic Targets
Current Pharmaceutical Design The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology Challenges with Mosquito-borne Viral Diseases: Outbreak of the Monsters
Current Topics in Medicinal Chemistry Age-Dependent Microglial Activation in Immature Brains After Hypoxia- Ischemia
CNS & Neurological Disorders - Drug Targets A Protective Role of Translocator Protein in Alzheimer’s Disease Brain
Current Alzheimer Research A Fatal Case of Acute Interstitial Pneumonia (AIP) in a Woman Affected by Glioblastoma
Current Drug Safety Anti-Ulcerogenic and Cytoprotective Effects of Saharian (Sidr) Honey from Algeria
Combinatorial Chemistry & High Throughput Screening Transcriptional Control of Collagen I Gene Expression
Cardiovascular & Hematological Disorders-Drug Targets Therapeutic Strategies to Target Multiple Kinases in Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy in the Transplantation of Allogeneic Organs and Stem Cells
Current Gene Therapy High-Density Lipoprotein Quantity or Quality for Cardiovascular Prevention?
Current Pharmaceutical Design The Utility of ADCC Responses in HIV Infection
Current HIV Research Targeting Invasion Induction as a Therapeutic Strategy for the Treatment of Cancer
Current Cancer Drug Targets A Developmental Approach to Drug-induced Liver Injury in Newborns and Children
Current Medicinal Chemistry SUBJECT INDEX TO VOLUME 1
Current Drug Safety Role of Serum and Glucocorticoid-Inducible Kinase (SGK)-1 in Senescence: A Novel Molecular Target Against Age-Related Diseases
Current Medicinal Chemistry The Interplay between Indoleamine 2,3-Dioxygenase 1 (IDO1) and Cyclooxygenase (COX)-2 In Chronic Inflammation and Cancer
Current Medicinal Chemistry Pertinence of Apoptosis Markers for the Improvement of In Vitro Fertilization (IVF)
Current Medicinal Chemistry